Literature DB >> 24155065

Ovarian reserve test: an impartial means to resolve the mismatch between chronological and biological age in the assessment of female reproductive chances.

Salvatore Gizzo1, Alessandra Andrisani, Federica Esposito, Alessandra Oliva, Cecilia Zicchina, Denise Capuzzo, Michele Gangemi, Giovanni Battista Nardelli.   

Abstract

Nowadays, the ovarian reserve (OR) is considered more important than chronological age to estimate female reproductive capability. We conducted a retrospective, observational, and cohort study in order to detect the best predictor marker of OR, ovarian response, chances to obtain high-quality embryos, and pregnancy after in vitro fertilization (IVF) cycle in elderly women. For all eligible patients (aged between 40 and 50 and admitted to their first IVF cycle for primary infertility), we investigated the biochemical parameters and ultrasound aspects of ovaries and how they affected IVF outcomes. Age, basal follicle-stimulating hormone, basal luteinizing hormone, and basal-17β-estradiol are better related to the dose of gonadotropin used during a controlled ovarian stimulation cycle. Basal anti-Müllerian hormone (AMH), antral follicular count (AFC), and maximum serum level of 17β-estradiol before pickup resulted the best predictors of chances to retrieve at least 6 oocytes (at least 3 in metaphase II) and to have at least 1 to 3 embryos. The basal AMH, AFC and maximum serum level of 17β-estradiol before pickup continue to show higher correlation to pregnancy rate. The maximum endometrial thickness at pickup resulted important to predict the pregnancy rate and the chances to detect ongoing pregnancy. It seems mandatory to well define the ovarian biological age rather than the chronological one in women older than 40 years of age in order to give the best counseling and to choose the most appropriate IVF protocols.

Entities:  

Keywords:  assisted reproduction techniques; biological ovarian age; chronological ovarian age; embryo quality; pregnancy rate

Mesh:

Year:  2013        PMID: 24155065     DOI: 10.1177/1933719113508821

Source DB:  PubMed          Journal:  Reprod Sci        ISSN: 1933-7191            Impact factor:   3.060


  9 in total

1.  Cost-effectiveness analysis comparing continuation of assisted reproductive technology with conversion to intrauterine insemination in patients with low follicle numbers.

Authors:  Bo Yu; Sunni Mumford; G Donald Royster; James Segars; Alicia Y Armstrong
Journal:  Fertil Steril       Date:  2014-06-18       Impact factor: 7.329

2.  Acute immunomodulatory changes during controlled ovarian stimulation: evidence from the first trial investigating the short-term effects of estradiol on biomarkers and B cells involved in autoimmunity.

Authors:  Anna Ghirardello; Salvatore Gizzo; Marco Noventa; Michela Quaranta; Amerigo Vitagliano; Nicoletta Gallo; Giorgia Pantano; Marianna Beggio; Chiara Cosma; Michele Gangemi; Mario Plebani; Andrea Doria
Journal:  J Assist Reprod Genet       Date:  2015-10-14       Impact factor: 3.412

Review 3.  Clinical management of endometriosis-associated infertility.

Authors:  Yin Mon Khine; Fuminori Taniguchi; Tasuku Harada
Journal:  Reprod Med Biol       Date:  2016-02-17

4.  Awareness of the effects of postponing motherhood among hospital gynecologists: is their knowledge sufficient to offer appropriate help to patients?

Authors:  Alberto Revelli; Alessandra Razzano; Luisa Delle Piane; Simona Casano; Chiara Benedetto
Journal:  J Assist Reprod Genet       Date:  2016-01-04       Impact factor: 3.412

Review 5.  Testosterone therapy for women with poor ovarian response undergoing IVF: a meta-analysis of randomized controlled trials.

Authors:  Marco Noventa; Amerigo Vitagliano; Alessandra Andrisani; Mija Blaganje; Paola Viganò; Enrico Papaelo; Marco Scioscia; Francesco Cavallin; Guido Ambrosini; Mauro Cozzolino
Journal:  J Assist Reprod Genet       Date:  2019-01-05       Impact factor: 3.412

6.  Recombinant LH supplementation during IVF cycles with a GnRH-antagonist in estimated poor responders: A cross-matched pilot investigation of the optimal daily dose and timing.

Authors:  Salvatore Gizzo; Alessandra Andrisani; Marco Noventa; Serena Manfè; Alessandra Oliva; Michele Gangemi; Giovanni Battista Nardelli; Guido Ambrosini
Journal:  Mol Med Rep       Date:  2015-06-09       Impact factor: 2.952

7.  Menstrual cycle length: a surrogate measure of reproductive health capable of improving the accuracy of biochemical/sonographical ovarian reserve test in estimating the reproductive chances of women referred to ART.

Authors:  Salvatore Gizzo; Alessandra Andrisani; Marco Noventa; Michela Quaranta; Federica Esposito; Decio Armanini; Michele Gangemi; Giovanni B Nardelli; Pietro Litta; Donato D'Antona; Guido Ambrosini
Journal:  Reprod Biol Endocrinol       Date:  2015-04-10       Impact factor: 5.211

Review 8.  Salpingectomy before assisted reproductive technologies: a systematic literature review.

Authors:  Marco Noventa; Salvatore Gizzo; Carlo Saccardi; Shara Borgato; Amerigo Vitagliano; Michela Quaranta; Pietro Litta; Michele Gangemi; Guido Ambrosini; Donato D'Antona; Stefano Palomba
Journal:  J Ovarian Res       Date:  2016-11-03       Impact factor: 4.234

9.  Pretreatment with oral contraceptive pills to identify poor responders that may benefit from rLH supplementation during GnRH-antagonist treatment for IVF: A pilot perspective study proposal.

Authors:  Salvatore Gizzo; Alessandra Andrisani; Marco Noventa; Michele Gangemi; Giovanni Battista Nardelli; Guido Ambrosini
Journal:  Exp Ther Med       Date:  2015-09-08       Impact factor: 2.447

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.